Skip Navigation

European Heart Journal 2003 24(12):1171-1173; doi:10.1016/S0195-668X(03)00194-5
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bassand, J.-P.
Right arrow Articles by Simoons, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bassand, J.-P.
Right arrow Articles by Simoons, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Regular Articles

The Need for Resources for Clinical Research

Proceedings of a Policy Conference held at the European Heart House, 27–28 June 2002: Executive Summary1

Jean-Pierre Bassand*, John Martin, Lars Rydén and Maarten Simoons

European Heart House, Sophia Antipolis, France

* Corresponding author. Tel.: +33-381-66-85-39; fax: +33-381-66-85-82
E-mail address: jean-pierre.bassand{at}ufc-chu.univ-fcomte.fr

Received 18 February 2003; accepted 19 February 2003

The medical profession, in particular cardiologists, acknowledge the fact that during the last 30 years, much of the progress made in the field of medicine has resulted from fruitful and close collaboration between academia and the pharmaceutical industry. However, during the last decade, this relationship has changed considerably. The industry increasingly carries out its own research, development of drugs and trials, according to its own agenda. As a result, academia has lost its influence.

This has led to a dramatic increase in the cost of clinical randomised trials. In the meantime, academic careers and research have become less attractive to physicians. Funding for research is increasingly devoted to basic science, in particular genomics, and little is left for clinical research. As a result, many important clinical trials in various areas of medicine, including cardiology, remain unfunded.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
K. Malmberg, L. Ryden, H. Wedel, K. Birkeland, A. Bootsma, K. Dickstein, S. Efendic, M. Fisher, A. Hamsten, J. Herlitz, et al.
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity
Eur. Heart J., April 1, 2005; 26(7): 650 - 661.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.